UBS Downgrades Jazz Pharmaceuticals (JAZZ) to Neutral, 'Balanced risk/reward'
Tweet Send to a Friend
(Updated - November 27, 2023 4:08 AM EST)
UBS analyst Ashwani Verma downgraded Jazz Pharmaceuticals (NASDAQ: JAZZ) from Buy ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
UBS analyst Ashwani Verma downgraded Jazz Pharmaceuticals (NASDAQ: JAZZ) from Buy ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
